Primary blasts from infants with acute lymphoblastic leukemia cause overt leukemia in SCID mice.
暂无分享,去创建一个
G. Reaman | F. Uckun | M. Sensel | P. Gaynon | B. Waurzyniak | L. Chelstrom | M. Crotty
[1] W. Evans,et al. In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (anti-CD7)-pokeweed antiviral protein immunotoxin. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[2] H. Sather,et al. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] N. Heerema,et al. Expression of BCR-ABL, E2A-PBX1, and MLL-AF4 fusion transcripts in newly diagnosed children with acute lymphoblastic leukemia: a Children's Cancer Group initiative. , 1997, Leukemia & lymphoma.
[4] H. Sather,et al. Improved clinical outcome for children with T-lineage acute lymphoblastic leukemia after contemporary chemotherapy: a Children's Cancer Group Study. , 1996, Leukemia & lymphoma.
[5] M. Seto,et al. Frequency and clinical significance of the MLL gene rearrangements in infant acute leukemia. , 1996, Leukemia.
[6] F. Behm,et al. Prognostic factors in the acute lymphoid and myeloid leukemias of infants. , 1996, Leukemia.
[7] J. Downing,et al. Rearrangement of the MLL gene confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age. , 1996, Blood.
[8] F. Mitelman. ISCN 1995 : an international system for human cytogenetic nomenclature (1995) : recommendations of the International Standing Committee on Human Cytogenetic Nomenclature : Memphis, Tennessee, USA, October 9-13, 1994 , 1995 .
[9] N. Tumer,et al. In vitro and in vivo antileukemic activity of B43-pokeweed antiviral protein against radiation-resistant human B-cell precursor leukemia cells. , 1995, Blood.
[10] N. Heerema,et al. Molecular analysis of infant acute lymphoblastic leukemia: MLL gene rearrangement and reverse transcriptase-polymerase chain reaction for t(4; 11)(q21; q23). , 1995, Blood.
[11] J. Jin,et al. In vitro and in vivo activity of topotecan against human B-lineage acute lymphoblastic leukemia cells. , 1995, Blood.
[12] C. Pui,et al. Biology and treatment of infant leukemias. , 1995, Leukemia.
[13] F. Lo Coco,et al. Prognostic relevance of ALL-1 gene rearrangement in infant acute leukemias. , 1995, Leukemia.
[14] A. Bleyer,et al. Leukemic cell growth in SCID mice as a predictor of relapse in high-risk B-lineage acute lymphoblastic leukemia. , 1995, Blood.
[15] G. Basso,et al. The role of immunophenotype in acute lymphoblastic leukemia of infant age. , 1994, Leukemia & lymphoma.
[16] J. Downing,et al. Human t(4;11)(q21;q23) acute lymphoblastic leukemia in mice with severe combined immunodeficiency. , 1994, Blood.
[17] S. Richards,et al. Acute lymphoblastic leukaemia in infancy: experience in MRC UKALL trials. Report from the Medical Research Council Working Party on Childhood Leukaemia. , 1994, Leukemia.
[18] J. Hilden,et al. The MLL (11q23) and AF-4 (4q21) genes disrupted in t(4;11) acute leukemia: molecular and clinical studies. , 1994, Leukemia & lymphoma.
[19] J. Downing,et al. 11q23/MLL rearrangement confers a poor prognosis in infants with acute lymphoblastic leukemia. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] N. Heerema,et al. Cytogenetic features of infants less than 12 months of age at diagnosis of acute lymphoblastic leukemia: impact of the 11q23 breakpoint on outcome: a report of the Childrens Cancer Group. , 1994, Blood.
[21] R. Gelber,et al. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Y. Bertrand,et al. Improved survival for acute lymphoblastic leukaemia in infancy: the experience of EORTC‐Childhood Leukaemia Cooperative Group , 1994, British journal of haematology.
[23] J. Downing,et al. Human t(1;19)(q23;p13) pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency. , 1993, Blood.
[24] S. Korsmeyer,et al. Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcome. , 1993, Blood.
[25] H. Sather,et al. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] J. Irvin,et al. In vivo anti-leukemic efficacy of anti-CD7-pokeweed antiviral protein immunotoxin against human T-lineage acute lymphoblastic leukemia/lymphoma in mice with severe combined immunodeficiency. , 1993, Leukemia.
[27] Dorothea,et al. Effective immunochemotherapy of CALLA+C mu+ human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19) pokeweed antiviral protein immunotoxin plus cyclophosphamide. , 1992, Blood.
[28] G. Basso,et al. The immunophenotype in infant acute lymphoblastic leukaemia: correlation with clinical outcome. An Italian multicentre study (AIEOP) , 1992, British journal of haematology.
[29] D. Arthur,et al. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency. , 1992, Blood.
[30] S. Kamel‐Reid,et al. Bone marrow from children in relapse with pre-B acute lymphoblastic leukemia proliferates and disseminates rapidly in scid mice. , 1991, Blood.
[31] J. Dick,et al. Transplantation of Normal and Leukemic Human Bone Marrow into Immune‐Deficient Mice: Development of Animal Models for Human Hematopoiesis , 1991, Immunological reviews.
[32] R. Foà,et al. Co‐expression of myeloid antigens in childhood acute lymphoblastic leukaemia: relationship with the stage of differentiation and clinical significance , 1991, British journal of haematology.
[33] B. Lange,et al. Homing and progression patterns of childhood acute lymphoblastic leukemias in severe combined immunodeficiency mice. , 1991, Blood.
[34] B. Haynes,et al. Successful engraftment of human postnatal thymus in severe combined immune deficient (SCID) mice: differential engraftment of thymic components with irradiation versus anti-asialo GM-1 immunosuppressive regimens , 1991, The Journal of experimental medicine.
[35] F. Uckun. Regulation of human B-cell ontogeny. , 1990, Blood.
[36] J. Dick,et al. A model of human acute lymphoblastic leukemia in immune-deficient SCID mice. , 1989, Science.
[37] J. Harbott,et al. Phenotypic and genotypic heterogeneity in infant acute leukemia. II. Acute nonlymphoblastic leukemia. , 1989, Leukemia.
[38] B. Koller,et al. Biphenotypic leukemic lymphocyte precursors in CD2+CD19+ acute lymphoblastic leukemia and their putative normal counterparts in human fetal hematopoietic tissues. , 1989, Blood.
[39] J. Ledbetter,et al. Immunobiologic differences between normal and leukemic human B-cell precursors. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[40] I. Weissman,et al. The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. , 1988, Science.
[41] Donald E. Mosier,et al. Transfer of a functional human immune system to mice with severe combined immunodeficiency , 1988, Nature.
[42] J. Ritter,et al. [Acute lymphoblastic leukemia in infancy: results of 5 multicenter ALL-BFM therapy studies 1970-1986]. , 1988, Klinische Padiatrie.
[43] H. Sather,et al. Improved survival of infants less than 1 year of age with acute lymphoblastic leukemia treated with intensive multiagent chemotherapy. , 1987, Cancer treatment reports.
[44] S. Raimondi,et al. An analysis of leukemic cell chromosomal features in infants. , 1987, Blood.
[45] A. Bleyer,et al. Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York regimen--a new intensive therapy protocol: a report from the Childrens Cancer Study Group. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] H. Sather,et al. Acute lymphoblastic leukemia in infants less than one year of age: a cumulative experience of the Children's Cancer Study Group. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] N. Heerema,et al. Karyotypic and clinical findings in a consecutive series of children with acute lymphocytic leukemia. , 1985, Cancer genetics and cytogenetics.
[48] J. Downing,et al. The der(11)-encoded MLL/AF-4 fusion transcript is consistently detected in t(4;11)(q21;q23)-containing acute lymphoblastic leukemia. , 1994, Blood.
[49] J. Okamura,et al. Infant leukemia in Japan: clinical and biological analysis of 48 cases. , 1991, Medical and pediatric oncology.